Build tomorrow’s portfolio today
Successful portfolio development starts well before a product reaches the market. Early visibility allows pharmaceutical companies to anticipate future opportunities, assess strategic fit and align internal commercial, regulatory and portfolio-planning priorities.
Pipeline focus portfolio
The Medis pipeline focus portfolio highlights selected opportunities that we believe are particularly relevant for forward-looking customer discussions. The selection spans oncology, hematology, diabetes and metabolic health, bringing together products that can support future portfolio expansion across important therapeutic areas.
Our aim is to help partners identify potential opportunities early, focus resources on the products most relevant to their strategy and begin evaluating market requirements in advance. These products are at different stages of development, and their dossier timing, intellectual-property position, registration pathway, territorial access and potential launch timing must be assessed individually.
For more information and to explore the suitability and timing of a pipeline opportunity for your desired market, please contact your relevant Medis Business Development Manager.
Oncology and Hematology
Azacitidine
An oral pipeline opportunity associated with maintenance therapy for adults with acute myeloid leukaemia.
- Dosage form: Film-coated tablet
- Strengths: 200 mg and 300 mg
- Therapeutic area: Antineoplastic and immunomodulating agents
- Key indication: Maintenance therapy for adults with acute myeloid leukaemia
- Product class: Antineoplastic agent and antimetabolite
- Dossier status: Available
- Estimated CPP timing: Q2 2027
The two-strength oral presentation may be relevant to future hematology and oncology portfolio planning.
Dabrafenib
A targeted-oncology pipeline opportunity associated with metastatic melanoma and non-small-cell lung cancer.
- Dosage form: Hard capsule
- Strengths: 50 mg and 75 mg
- Therapeutic area: Antineoplastic and immunomodulating agents
- Key indications: Metastatic melanoma and non-small-cell lung cancer
- Product class: Protein kinase inhibitor
- Expected dossier availability: Q4 2026
- Estimated CPP timing: Q3 2028
The two-strength capsule presentation may be relevant to partners developing future targeted-oncology portfolios.
Enzalutamide
An oral oncology pipeline opportunity associated with prostate cancer.
- Dosage form: Film-coated tablet
- Strengths: 40 mg and 80 mg
- Therapeutic area: Antineoplastic and immunomodulating agents
- Key indication: Prostate cancer
- Product class: Endocrine therapy
- Dossier status: Available
- Stability coverage: Zone IVb
- Estimated CPP timing: Available
The two-strength film-coated tablet presentation supports early discussions with oncology-focused partners.
Palbociclib
An oral pipeline opportunity associated with the treatment of breast cancer.
- Dosage form: Film-coated tablet
- Strengths: 75 mg, 100 mg and 125 mg
- Therapeutic area: Antineoplastic and immunomodulating agents
- Key indication: Breast cancer
- Product class: Protein kinase inhibitor
- Dossier status: Available
- Estimated CPP timing: Q4 2026
The three-strength presentation may support future portfolio planning within oncology and breast-cancer treatment.
Ruxolitinib
A multi-strength hematology pipeline opportunity associated with myelofibrosis.
- Dosage form: Tablet
- Strengths: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg
- Therapeutic area: Antineoplastic and immunomodulating agents
- Key indication: Myelofibrosis
- Product class: Protein kinase inhibitor
- Dossier status: Available
- Estimated CPP timing: Q1 2027
The five-strength range, including the 25 mg presentation, provides a broad product configuration for hematology-focused portfolio discussions.
Trametinib
A targeted-oncology pipeline opportunity associated with metastatic melanoma.
- Dosage form: Film-coated tablet
- Strengths: 0.5 mg and 2 mg
- Therapeutic area: Antineoplastic and immunomodulating agents
- Key indication: Metastatic melanoma
- Product class: Protein kinase inhibitor
- Dossier status: Available
- Estimated CPP timing: Q3 2027
The two-strength film-coated tablet presentation may complement future targeted-oncology portfolios.
Diabetes and Metabolic Health
Dapagliflozin
A single-agent oral pipeline opportunity associated with type 2 diabetes mellitus.
- Dosage form: Film-coated tablet
- Strengths: 5 mg and 10 mg
- Therapeutic area: Alimentary tract and metabolism
- Key indication: Type 2 diabetes mellitus
- Product class: Blood-glucose-lowering agent
- Dossier status: Available
- Stability coverage: Zone IVb
- Estimated CPP timing: Available
The two-strength presentation may support partners seeking to develop or extend an oral diabetes portfolio.
Dapagliflozin / Metformin
A fixed-dose combination pipeline opportunity associated with type 2 diabetes mellitus.
- Dosage form: Film-coated tablet
- Strengths: 5 mg/850 mg and 5 mg/1000 mg
- Therapeutic area: Alimentary tract and metabolism
- Key indication: Type 2 diabetes mellitus
- Product class: Blood-glucose-lowering agent
- Dossier status: Available
- Estimated CPP timing: Q2 2027
The two fixed-dose strengths may complement the single-agent Dapagliflozin opportunity and support broader diabetes portfolio planning.
Empagliflozin
A two-strength oral pipeline opportunity associated with type 2 diabetes mellitus.
- Dosage form: Film-coated tablet
- Strengths: 10 mg and 25 mg
- Therapeutic area: Alimentary tract and metabolism
- Key indication: Type 2 diabetes mellitus
- Product class: Blood-glucose-lowering agent
- Dossier status: Available
- Stability coverage: Zone IVb
- Estimated CPP timing: Q2 2028
The two-strength presentation provides an additional potential opportunity within the selected diabetes pipeline.
Important Product Information
Medis partners with pharmaceutical companies and does not supply medicines directly to patients or healthcare professionals.
The information presented on this page is intended exclusively for business-to-business discussions. Product specifications, dosage forms, strengths, indications, dossier status, development timing, manufacturing arrangements, intellectual-property position, registration pathway, marketing-authorization availability, supply conditions and launch timing may vary by country and may change.
A dossier described as available may not necessarily be immediately suitable for submission or commercial launch in every territory. Additional development, documentation, regulatory activities or market-specific requirements may apply.
Indications shown are high-level portfolio descriptors and do not constitute prescribing information, medical advice or confirmation of an approved indication in a particular country.
For detailed product information and to assess the suitability of an opportunity for your desired market, please contact your relevant Medis Business Development Manager.